Severe peripheral oedema temporally associated with accelerated infliximab induction for acute severe ulcerative colitis
Authors: Anna Gontar, Youssef Hafez, Manar Shmais
Journal: BMJ Case Reports
Publication year: 2026
Abstract
Infliximab is an established rescue therapy for steroid-refractory acute severe ulcerative colitis and is increasingly given as accelerated induction. A woman in her mid-50s with steroid-refractory disease received infliximab-abda 10 mg/kg on days 1, 4 and 15, with clinical and biochemical response. Four days after discharge, she developed severe bilateral pitting lower limb oedema, refractory to high-dose loop diuretics. Cardiac, renal, hepatic and thrombotic causes were evaluated and considered unlikely, and the oedema was disproportionate to serum albumin, which had already normalised. Oedema recurred within 3 days of a delayed maintenance infusion on day 64, when the infliximab trough was 27 µg/mL with undetectable anti-drug antibodies. Naranjo scoring indicated a probable adverse drug reaction. Infliximab was permanently withdrawn and treatment changed to guselkumab, after which the oedema resolved. Drug-related oedema merits consideration once common systemic causes have been assessed.